OpGen Inc. Announces Special Meeting of Stockholders on May 9, 2024
Ticker: CFOR · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1293818
| Field | Detail |
|---|---|
| Company | Opgen Inc (CFOR) |
| Form Type | DEF 14A |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $1.00, $3.0 million, $0.01, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Special Meeting, Securities Purchase Agreement, Convertible Preferred Stock, David E. Lazar
TL;DR
<b>OpGen, Inc. is holding a virtual Special Meeting of Stockholders on May 9, 2024, to discuss a $3.0 million securities purchase agreement with David E. Lazar.</b>
AI Summary
OPGEN INC (CFOR) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. OpGen, Inc. will hold a Special Meeting of Stockholders on May 9, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted exclusively via online audio-only broadcast at www.virtualshareholdermeeting.com/OPGN2024SM. On March 25, 2024, OpGen entered into a Securities Purchase Agreement with David E. Lazar. David E. Lazar agreed to acquire 3,000,000 shares of Series E Convertible Preferred Stock at $1.00 per share. The aggregate gross proceeds from this agreement are $3.0 million.
Why It Matters
For investors and stakeholders tracking OPGEN INC, this filing contains several important signals. The virtual format allows for broader participation but may limit direct interaction compared to in-person meetings. The securities purchase agreement with David E. Lazar provides a significant capital infusion, which could impact the company's financial stability and future operations.
Risk Assessment
Risk Level: low — OPGEN INC shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new material financial information or significant operational updates, indicating a low level of immediate risk.
Analyst Insight
Review the details of the Securities Purchase Agreement with David E. Lazar and its implications for OpGen's capital structure and future funding.
Key Numbers
- May 9, 2024 — Special Meeting Date (OpGen, Inc. Special Meeting of Stockholders)
- 10:00 a.m. Eastern Time — Meeting Time (OpGen, Inc. Special Meeting of Stockholders)
- March 25, 2024 — Purchase Agreement Date (Agreement between OpGen and David E. Lazar)
- 3,000,000 — Series E Preferred Shares (To be acquired by David E. Lazar)
- $1.00 — Price Per Share (Series E Convertible Preferred Stock)
- $3.0 million — Gross Proceeds (From Series E Convertible Preferred Stock sale)
Key Players & Entities
- OPGEN INC (company) — Registrant
- David E. Lazar (person) — Party to Securities Purchase Agreement
- May 9, 2024 (date) — Date of Special Meeting
- March 25, 2024 (date) — Date of Purchase Agreement
- 3,000,000 (dollar_amount) — Shares of Series E Convertible Preferred Stock
- $1.00 (dollar_amount) — Price per share
- $3.0 million (dollar_amount) — Aggregate gross proceeds
FAQ
When did OPGEN INC file this DEF 14A?
OPGEN INC filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by OPGEN INC (CFOR).
Where can I read the original DEF 14A filing from OPGEN INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by OPGEN INC.
What are the key takeaways from OPGEN INC's DEF 14A?
OPGEN INC filed this DEF 14A on April 26, 2024. Key takeaways: OpGen, Inc. will hold a Special Meeting of Stockholders on May 9, 2024, at 10:00 a.m. Eastern Time.. The meeting will be conducted exclusively via online audio-only broadcast at www.virtualshareholdermeeting.com/OPGN2024SM.. On March 25, 2024, OpGen entered into a Securities Purchase Agreement with David E. Lazar..
Is OPGEN INC a risky investment based on this filing?
Based on this DEF 14A, OPGEN INC presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new material financial information or significant operational updates, indicating a low level of immediate risk.
What should investors do after reading OPGEN INC's DEF 14A?
Review the details of the Securities Purchase Agreement with David E. Lazar and its implications for OpGen's capital structure and future funding. The overall sentiment from this filing is neutral.
How does OPGEN INC compare to its industry peers?
OpGen, Inc. operates in the healthcare sector, likely focusing on diagnostics or related services, as indicated by its SIC code 8071 (Services-Medical Laboratories).
Are there regulatory concerns for OPGEN INC?
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
Industry Context
OpGen, Inc. operates in the healthcare sector, likely focusing on diagnostics or related services, as indicated by its SIC code 8071 (Services-Medical Laboratories).
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
What Investors Should Do
- Review the terms of the Series E Convertible Preferred Stock and its conversion rights.
- Analyze the potential impact of the $3.0 million capital infusion on OpGen's financial position.
- Prepare for participation in the virtual Special Meeting on May 9, 2024.
Key Dates
- 2024-05-09: Special Meeting of Stockholders — To be held virtually to discuss company matters, including a securities purchase agreement.
- 2024-04-26: Filing Date — Date of the Definitive Proxy Statement (DEF 14A).
- 2024-03-25: Securities Purchase Agreement Date — Agreement entered into with David E. Lazar for Series E Preferred Stock.
Year-Over-Year Comparison
This filing is a DEF 14A, indicating a definitive proxy statement, which is a standard disclosure for upcoming shareholder meetings and does not represent a change from previous filings in terms of format or purpose.
Filing Stats: 4,799 words · 19 min read · ~16 pages · Grade level 11.8 · Accepted 2024-04-26 07:30:14
Key Financial Figures
- $1.00 — ck”) of the Company at a price of $1.00 per share for aggregate gross proceeds
- $3.0 million — r share for aggregate gross proceeds of $3.0 million. Each share of Series E Preferred Stock
- $0.01 — n shares of our common stock, par value $0.01 per share, or preferred stock, par valu
- $10,000 — ned, we estimate would be approximately $10,000. We will reimburse banks, brokers, nomi
Filing Documents
- opgen_def14a.htm (DEF 14A) — 440KB
- img_001.jpg (GRAPHIC) — 5KB
- 0001829126-24-002814.txt ( ) — 447KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 PROPOSALS TO BE ACTED UPON AT THE SPECIAL MEETING 9 PROPOSAL NO. ONE – SHARE ISSUANCE AND CHANGE OF CONTROL PROPOSAL 9 PROPOSAL NO. TWO – REVERSE STOCK SPLIT PROPOSAL 12 PROPOSAL NO. THREE – ADJOURNMENT PROPOSAL 18 OTHER MATTERS 19 DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS 20 STOCKHOLDER PROPOSALS 21 i 9717 Key West Ave, Suite 100 Rockville, MD 20850 SPECIAL MEETING PROXY STATEMENT IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 9, 2024 The Notice of Special Meeting, Proxy Statement and Proxy are available at: https://annualgeneralmeetings.com/opgnsp2024 We are making these proxy materials available to you in connection with the solicitation of proxies by the Board of Directors (the “Board”) of OpGen, Inc. (the “Company”) for a Special Meeting of Stockholders (the “Special Meeting”) and for any adjournment or postponement of the Special Meeting. The mailing of the notice of internet availability of these proxy materials will commence on April 26, 2024. This Special Meeting will be a “virtual meeting” of stockholders, which will be conducted exclusively via online audio-only broadcast. You will be able to participate in the Special Meeting, vote your shares and submit your questions during the meeting via the Internet by visiting www.virtualshareholdermeeting.com/OPGN2024SM . The Special Meeting will be held in virtual format only. In this Proxy Statement, “we,” “us,” “our,” “OpGen” and the “Company” refer to OpGen, Inc. This Proxy Statement is being made available to you because you own shares of our common stock, par value $0.01 per share, or preferred stock, par value $0.01 per share, as of the record date, which entitles you to vote at the Specia